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Hepatitis C cross-genotype 
immunity and implications for 
vaccine development
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Jason Wong1,2, Mark W. Tyndall1,2, Naveed Zafar Janjua1,2 & The BC-HTC Team*
While about a quarter of individuals clear their primary hepatitis C (HCV) infections spontaneously, 
clearance (spontaneous or treatment-induced) does not confer sterilizing immunity against a future 
infection. Since successful treatment does not prevent future infections either, an effective vaccine 
is highly desirable in preventing HCV (re)infection. However, development of an effective vaccine 
has been complicated by the diversity of HCV genotypes, and complexities in HCV immunological 
responses. Smaller studies on humans and chimpanzees reported seemingly opposing results regarding 
cross-neutralizing antibodies. We report a lack of cross-genotype immunity in the largest cohort of 
people to date. In the adjusted Cox proportional hazards model, reinfection with a heterologous HCV 
genotype (adjusted Hazard Ratio [aHR]: 0.45, 95% CI: 0.25–0.84) was associated with a 55% lower 
likelihood of re-clearance. Among those who cleared their first infection spontaneously, the likelihood 
of re-clearance was 49% lower (aHR: 0.51, 95% CI: 0.27–0.94) when reinfected with a heterologous 
HCV genotype. These findings indicate that immunity against a particular HCV genotype does not 
offer expanded immunity to protect against subsequent infections with a different HCV genotype. A 
prophylactic HCV vaccine boosted with multiple HCV genotype may offer a broader and more effective 
protection.
Ability to clear an episode of hepatitis C virus (HCV) infection, spontaneously1,2 or after a successful treatment, 
does not protect against a future infection3–11. New DAAs are highly effective but prohibitively expensive, and 
there is no effective vaccine against HCV12. As we wait for an effective vaccine against HCV, studies on humans 
and chimpanzees provide important insights into developing such vaccine13. Previous studies in chimpanzees14–16, 
and humans17,18, indicated that compared to primary infection, exposure to a subsequent infection was associated 
a lower peak viremia, overall shortened infection course and lower ALT, and a higher likelihood of viral clearance. 
While earlier case studies reported similar findings17,18, including cross-neutralizing antibodies17, this has not 
been examined in larger population-based studies before. Studies on Chimpanzees reported seemingly oppos-
ing results15,16. Some animal data reported cross-genotype immunity15, while other findings suggested limited 
protection against heterologous HCV viral strains16,19. While these findings are important in understanding the 
natural history of HCV to lend support to vaccine development, these, and other epidemiological studies7,17,18,20,21 
had very small sample size that may have compromised their generalizability and their ability to examine factors 
determining the outcome following HCV reinfection. The studies on humans published so far summarized clear-
ance of reinfection as case reports or case series except one study22 that only reported unadjusted estimates, and 
was unable to examine factors associated with HCV re-clearance adjusting for other potential confounders due 
to very small sample size (n = 14). In this study, we examined if reinfection with a heterologous HCV genotype 
had any impact on re-clearance.
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Results
Of 452 cases of reinfection, 357 participants had at least one valid HCV-PCR tests after reinfection. They were fol-
lowed up for a median of 26.7 (IQR: 12.2–53.8) months post-reinfection. Almost half (49%; n = 175) of them had 
at least one negative HCV-PCR after reinfection; 121 (34%) of them had two consecutive negative PCR at least 28 
days apart (confirmed re-clearance), and the rest (15%; n = 54) had either only one negative PCR, or two consec-
utive negative PCR < 28 days apart (probable re-clearance). Individuals included in this study had a median of 12 
(IQR: 9–16) HCV-PCR tests overall with a median of 5 (IQR: 3–8; range: 2–33) HCV-PCR tests after reinfection. 
The median testing interval post-reinfection was 5.5 (IQR: 2.2–12.1) months. Study participants were observed 
for a median of 24.0 (IQR: 9.2–56.5) months to examine the spontaneous clearance of first infection, and 34.4 
(IQR: 16.2–61.8) months to develop reinfection before entering the current study.
Table 1 shows the characteristics of the sample population. The majority of the participants were male (64%; 
n = 228), and 35–44 years old at reinfection (39%; n = 139). The proportion of people who inject drugs (PWID), 
and people co-infected with HIV in this sample was 39% (n = 140), and 21% (n = 76), respectively. While more 
than a fifth (22%; n = 78) had an ongoing history of problematic alcohol use, almost a quarter (24%; n = 86) had 
a current history of major mental illness. Most of them (90%; n = 323) cleared their first infection spontaneously, 
and 18% (n = 63) had a reinfection episode with a heterologous HCV genotype.
In the adjusted analysis, reinfection with a heterologous HCV genotype (adjusted Hazard Ratio [aHR]: 0.45, 
95% CI: 0.25–0.84), was significantly associated with a 55% lower likelihood of HCV re-clearance (Table 2). 
Among those who cleared their first infections spontaneously, reinfection with a heterologous genotype was 
associated with a 49% lower likelihood (aHR: 0.51, 95% CI: 0.27–0.94) of HCV re-clearance adjusting for other 
potential confounders (Table 3). The propensity score-based IPTW-weighted Cox proportional hazards model 
also yielded similar results (aHR: 0.32, 95% CI: 0.23–0.45 in the full cohort, and aHR: 0.37, 95% CI: 0.26–0.52 
among those who spontaneously cleared their first infection). The results were similar in the sensitivity analysis 
combining probable and confirmed re-clearance (Supplementary Table 3), and also in the logistic regression 
models (Supplementary Table 4).
We further analyzed the data to see if re-clearance was associated with the sequence of HCV genotypes (GT). 
Compared to those who were infected with GT1 in both of their episodes, those infected with GT2/3 in both their 
infection episodes showed a slightly reduced likelihood of re-clearance but it did not reach statistical significance 
(aHR: 0.56, 95% CI: 0.21–1.51, p = 0.254). Further, compared to those without reinfection with a heterologous 
HCV genotype, those who were infected with GT1 followed by a second infection with GT2/3 showed a higher 
likelihood of re-clearance (aHR: 1.31, 95% CI: 0.47–3.65, p = 0.601), but those who were infected with GT2/3 
followed by a second infection with GT1 showed a lower likelihood of re-clearance (aHR: 0.62, 95% CI: 0.23–1.70, 
p = 0.354). Again, none of these reached statistical significance.
Discussion
To our knowledge, this is the largest study thus far to examine HCV re-clearance in humans. Consistent with 
earlier reports, the rate of spontaneous clearance of reinfection was much higher than that of first infection2. We 
also showed that reinfection with a heterologous HCV genotype was associated with a significant reduction in the 
likelihood of re-clearance among those who cleared their first HCV episode spontaneously indicating a lack of 
cross-genotype protective immune response against subsequent infections.
In our study, the proportion of confirmed re-clearance was 34%. Studies previously reported a wide range of 
estimates (0–100%)17,18,20,22. Even though the rate of re-clearance (per person-year) was not reported earlier, the 
proportion of re-clearance was reported to be higher than the clearance of the first infection in smaller studies in 
chimpanzees and humans17,18,20,22,23. Our findings align with these findings.
We found a significantly reduced likelihood of HCV re-clearance when reinfected with a heterologous gen-
otype, and among those who had an ongoing history of problematic alcohol use. Though not evaluated in the 
context of HCV re-clearance, alcohol abuse was reported to be associated with reduced odds of spontaneous 
clearance of HCV24. Alcohol abuse was found to worsen the clinical outcomes of HCV in humans by altering 
the immune response to HCV, particularly by inhibiting the T-cell activating capacity25,26. The only study that 
examined the potential factors associated with re-clearance found females with the IFNL4 rs12979860 CC geno-
type a significant predictor, even though it was not adjusted for other potential confounders22. While female sex 
was not a significant predictor in our adjusted analysis, we did not have data on IFNL4, and so we were not able 
to examine this. Further studies with sufficient sample size to adjust for potential confounders are required to 
validate these findings.
Among those who cleared their previous HCV episode spontaneously, we found that reinfection with a het-
erologous genotype was associated with a significantly lower likelihood of re-clearance. While earlier case stud-
ies reported similar findings17,18, including cross-neutralizing antibodies17, this has not been examined in larger 
population-based studies before. Studies on chimpanzees reported seemingly opposing results15,16. Some animal 
data reported cross-genotype immunity15, while other findings suggested limited protection against heterologous 
HCV viral strains16,19.
Besides testing the robustness of our findings by a series of additional analysis including the application of 
propensity score methods to address the issue of confounding by indication, we further assessed the effect of 
sequence of genotypes on re-clearance and found that people who were infected with genotype 1 followed by gen-
otype 2/3 were more likely to clear their second infection spontaneously while those infected with genotype 2/3 
in their first infection followed by genotype 1 infection were less likely to clear their 2nd infection. None of these 
associations reached statistical significance. Because this was not in our primary hypotheses tested in this study, 
caution should be exercised in interpreting these findings, and we recommend further studies with larger sample 
size to characterize impact of specific genotype sequences.
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Characteristics
Re-clearance
Confirmed* 
(N = 121)
Probable† 
(N = 54)
No 
(N = 182)
Age at HCV reinfection (years)
<35 37 (30.6) 14 (25.9) 49 (26.9)
35–44 47 (38.8) 25 (46.3) 67 (36.8)
≥45 37 (30.6) 15 (27.8) 66 (36.3)
Birth cohort
<1964 54 (44.6) 27 (50.0) 81 (44.5)
1965–1974 38 (31.4) 14 (25.9) 61 (33.5)
≥1975 29 (24.0) 13 (24.1) 40 (22.0)
Sex
Female 39 (32.2) 28 (51.9) 62 (34.1)
Male 82 (67.8) 26 (48.2) 120 (65.9)
Year of HCV diagnosis
1990–1997 50 (41.3) 15 (27.8) 58 (31.9)
1998–2004 48 (39.7) 25 (46.3) 96 (52.8)
2005–2013 23 (19.0) 14 (25.9) 28 (15.4)
HCV heterologous genotype
Yes 12 (9.9) 8 (14.8) 43 (23.6)
No 109 (90.1) 46 (85.2) 139 (76.4)
Clearance type‡
Spontaneous clearance 114 (94.2) 50 (92.6) 159 (87.4)
Sustained virological response 7 (5.8) 4 (7.4) 23 (12.6)
HIV**
Yes 24 (19.8) 8 (14.8) 44 (24.2)
No 97 (80.2) 46 (85.2) 138 (75.8)
Major mental illness***
Yes 26 (21.5) 14 (25.9) 46 (25.3)
No 95 (78.5) 40 (74.1) 136 (74.7)
Injection drug use***
Yes 47 (38.8) 24 (44.4) 69 (37.9)
No 74 (61.2) 30 (55.6) 113 (62.1)
Problematic alcohol use***
Yes 19 (15.7) 16 (29.6) 43 (23.6)
No 102 (84.3) 38 (70.4) 139 (76.4)
Material deprivation quintile at reinfection
Q1 (most privileged) 16 (13.2) 3 (5.6) 27 (14.8)
Q2 19 (15.7) 11 (20.4) 28 (15.4)
Q3 18 (14.9) 6 (11.1) 24 (13.2)
Q4 32 (26.5) 14 (25.9) 35 (19.2)
Q5 (most deprived) 30 (24.8) 16 (29.6) 62 (34.1)
Unknown 6 (5.0) 4 (7.4) 6 (3.3)
Social deprivation quintile at reinfection
Q1 (most privileged) 12 (9.9) 4 (7.4) 11 (6.0)
Q2 11 (9.1) 5 (9.3) 20 (11.0)
Q3 14 (11.6) 6 (11.1) 21 (11.5)
Q4 30 (24.8) 11 (20.4) 28 (15.4)
Q5 (most deprived) 48 (39.7) 24 (44.4) 96 (52.8)
Unknown 6 (5.0) 4 (7.4) 6 (3.3)
Table 1. Characteristics of participants assessed for hepatitis C virus re-clearance in British Columbia, 
Canada. *Two consecutive negative PCR, at least 28 days apart; †Either one negative PCR, or two 
consecutive negative PCR but the difference between them was less than 28 days; ‡Clearance type of the 
first HCV infection; **Any time before the last day of follow-up; ***Any time during the study follow-up 
time. HCV: Hepatitis C Virus; HIV: Human Immunodeficiency Virus; PCR = Polymerase Chain Reaction 
(RNA testing for HCV).
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To our knowledge, this is the first population-based comprehensive study with the largest sample size to exam-
ine spontaneous clearance of HCV reinfection. We collected data on other potential confounders to examine the 
factors associated with HCV re-clearance making it the first study to do so. However, some of the limitations of 
this study include our inability to examine the impact of ethnicity, and genetic markers including IFNL4.
Conclusions
While we wait for an effective vaccine to offer sterilizing immunity, it is probably more pragmatic to develop 
a prophylactic vaccine that augments spontaneous clearance of HCV inducing partial protective immunity12. 
Lessons from other vaccines (e.g. those against hepatitis B, human papilloma, influenza, and varicella zoster)27, 
which, instead of providing sterilizing immunity, protect against persistent infections and result in a weakened 
course of infections may be relevant for HCV. Within the context of limited protection against heterologous gen-
otypes shown in our study, immunization with prophylactic vaccine, and boosting with different HCV genotypes 
have been suggested for a broader and more effective protection19.
Methods
The data for this analysis is based on the BC Hepatitis Testers Cohort (BC-HTC)2,28,29 that includes all individ-
uals tested for HCV or HIV at the BC Centre for Disease Control Public Health Laboratory (BCCDC-PHL) or 
reported case of HCV, HBV, or HIV, and linked with data on demographic characteristicsS6, medical visitsS2, hos-
pitalizationsS1, and prescription drugs (including HCV treatment)S3,S4 (Supplementary Table 1). BCCDC-PHL is 
the centralized laboratory for most serology (>95%) and all HCV RNA (PCR) testing in BC, and thus provides 
a unique tool to monitor and assess the impact of HCV treatment and harm reduction initiatives across the 
Characteristics
Unadjusted HR 
(95% CI) p-value
Adjusted HR 
(95% CI) p-value
Age at HCV reinfection (years) 0.579 0.225
<35 1.27 (0.81–2.01) 1.48 (0.92–2.38)
35–44 1.11 (0.72–1.70) 1.36 (0.88–2.10)
≥45 Ref Ref
Birth cohort 0.661
<1965 0.81 (0.52–1.28)
1965–1974 0.89 (0.55–1.44)
≥1975 Ref
Female 0.86 (0.59–1.26) 0.444 0.78 (0.52–1.16) 0.213
Year of HCV diagnosis 0.01 0.02
1990–1997 0.67 (0.41–1.12) 0.69 (0.41–1.16)
1998–2004 0.47 (0.28–0.77) 0.49 (0.29–0.82)
2005–2013 Ref Ref
HCV heterologous genotype 0.47 (0.26–0.86) 0.014 0.45 (0.25–0.84) 0.012
Spontaneous clearance‡ 1.7 (0.79–3.64) 0.176
HIV** 0.86 (0.55–1.34) 0.498
Major mental illness*** 0.71 (0.46–1.09) 0.117
Injection drug use*** 0.79 (0.55–1.15) 0.219
Problematic alcohol use*** 0.50 (0.30 –0.81) 0.005 0.47 (0.29–0.78) 0.004
Material deprivation quintile at reinfection 0.803
Q1 (most privileged) Ref
Q2 0.95 (0.48–1.86)
Q3 1.03 (0.52–2.04)
Q4 1.03 (0.56–1.88)
Q5 (most deprived) 0.74 (0.40–1.36)
Unknown 1.05 (0.41–2.69)
Social deprivation quintile at reinfection 0.344
Q1 (most privileged) Ref
Q2 0.68 (0.30–1.55)
Q3 0.83 (0.38–1.80)
Q4 0.98 (0.50 –1.92)
Q5 (most deprived) 0.61 (0.32–1.14)
Unknown 0.85 (0.32–2.26)
Table 2. Unadjusted and adjusted hazard ratios for factors associated with hepatitis C virus re-clearance 
(confirmed) in British Columbia, Canada. ‡Clearance type of the first HCV infection. **Used as a time-
varying covariate. ***Any time during the study follow-up time. HCV: Hepatitis C Virus; HIV: Human 
Immunodeficiency Virus; HR: Hazard Ratio: CI: Confidence Interval.
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natural history of HCV. Details of the BC-HTC including creation, linkage, characteristics, and matching have 
been reported previously28. Current analysis included all HCV reinfected individuals who had at least one valid 
HCV-PCR after reinfection, and who did not receive HCV treatment after reinfection.
An HCV case is an individual who tested positive for either HCV antibody or HCV-PCR or genotype, or who 
was reported as a case of HCV in the Integrated Public Health Information System (iPHIS)28. HCV diagnosis date 
was the date of HCV positive test for those testing positive on the first test while it was the midpoint between the 
last negative HCV date and the first time they tested positive for HCV for those who tested negative for HCV at 
first test, and subsequently tested positive for HCV (seroconverters).
Spontaneous clearance was defined as two consecutive negative HCV-PCR tests, at least 28 days apart22, fol-
lowing HCV diagnosis without treatment. The date of spontaneous clearance was calculated as the midpoint 
between the last positive and first negative PCR following HCV diagnosis22. Sustained virological response (SVR) 
was defined as two consecutive negative HCV-PCR tests, at least 28 days apart22, at ≥12 weeks post-treatment 
completion (the date of last dispensation of HCV treatment plus the days the drug was dispensed for)30. The date 
of SVR was calculated as the midpoint between the 12-weeks post-treatment end date and the subsequent first 
negative PCR date.
HCV reinfection was defined as a positive HCV-PCR following clearance (spontaneous clearance or SVR) of 
first infection. The date of reinfection was calculated as the midpoint between the last negative PCR and the first 
positive PCR following clearance of the first infection.
HCV re-clearance (confirmed) was defined as two consecutive negative PCR tests, at least 28 days apart, after 
reinfection. Those who had only one negative HCV-PCR, or two consecutive negative PCR within a 28-day time 
frame, were defined as probable re-clearance. The date of re-clearance was the midpoint between the last positive 
and the first negative PCR after reinfection. Time from reinfection to re-clearance was the main outcome variable.
Characteristics Unadjusted HR (95% CI) p-value Adjusted HR (95% CI) p-value
Age at HCV reinfection (years) 0.541 0.211
<35 1.30 (0.81–2.10) 1.50 (0.92–2.44)
35–44 1.19 (0.75–1.87) 1.42 (0.90–2.24)
≥45 Ref Ref
Birth cohort 0.47
<1965 0.78 (0.49–1.24)
1965–1974 0.96 (0.59–1.57)
≥1975 Ref
Female 0.83 (0.56–1.22) 0.337 0.75 (0.49–1.12) 0.16
Year of HCV diagnosis 0.019 0.024
1990–1997 0.63 (0.38–1.06) 0.63 (0.37–1.07)
1998–2004 0.48 (0.29–0.80) 0.49 (0.29–0.82)
2005–2013 Ref Ref
HCV heterologous genotype 0.57 (0.32–1.04) 0.069 0.51 (0.27–0.94) 0.031
HIV** 0.91 (0.58–1.42) 0.672
Major mental illness*** 0.79 (0.50–1.23) 0.287
Injection drug use*** 0.87 (0.60–1.26) 0.459
Problematic alcohol use*** 0.53 (0.33–0.87) 0.012 0.50 (0.30–0.83) 0.008
Material deprivation quintile at reinfection 0.868
Q1 (most privileged) Ref
Q2 0.92 (0.46–1.86)
Q3 1.00 (0.49–2.01)
Q4 1.01 (0.54–1.88)
Q5 (most deprived) 0.74 (0.39–1.39)
Unknown 0.98 (0.38–2.54)
Social deprivation quintile at reinfection 0.25
Q1 (most privileged) Ref
Q2 0.78 (0.34–1.80)
Q3 0.71 (0.30–1.66)
Q4 1.22 (0.61–2.44)
Q5 (most deprived) 0.69 (0.36–1.33)
Unknown 0.90 (0.33–2.43)
Table 3. Unadjusted and adjusted hazard ratios for factors associated with hepatitis C virus re-clearance 
(confirmed) in British Columbia, Canada (restricted to those who spontaneously cleared their first HCV 
infection). **Used as a time-varying covariate. ***Any time within the study follow-up time. HCV: Hepatitis C 
Virus; HIV: Human Immunodeficiency Virus; HR: Hazard Ratio: CI: Confidence Interval.
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HIV cases were identified based on reporting to the HIV/AIDS Information System (HAISYS), which includes 
all HIV/AIDS cases reported in BC, or HIV lab tests as per provincial guidelines31. Additional cases who tested 
without nominal information were identified through a previously validated algorithm based on medical visits 
and/or hospital admissions described elsewhere28. Major mental illness, injection drug use (IDU), and problem-
atic alcohol use were defined based on diagnostic codes from medical services plan or discharge abstract data-
base (DAD). Details including the International Classification of Diseases [ICD]) codes have been provided in 
Supplementary Table 2. The heterologous genotype was defined as reinfections with an HCV genotype other than 
the one in first infection. We also assessed the social and material deprivation based on Québec Index of Material 
and Social Deprivation.
Variables based on a-priori hypotheses, and those significant at 0.10 level in the unadjusted analysis were 
included in the multivariable Cox proportional hazards (PH) models. For the main analyses, time to con-
firmed re-clearance was the main outcome variable (probable and no re-clearance were censored). The last day 
of follow-up was the date of re-clearance, or last positive date after reinfection or the date a person received 
any treatment, whichever came first. Age at reinfection, sex, and year of HCV diagnosis were included in all 
the adjusted analyses irrespective of their statistical significance in the unadjusted analysis. HIV was used as a 
time-varying covariate in all the analyses.
To assess the role of reinfection with a heterologous genotype on spontaneous re-clearance among those 
who spontaneously cleared their first infection, we performed an additional analysis restricted to those who 
cleared their first infection spontaneously. Multinomial logistic regression was fit to assess the robustness of the 
time-to-event analysis. Propensity score methods were applied to calculate the inverse probability of treatment 
weight (IPTW). IPTW-weighted Cox PH model was fitted to address the issue of treatment-indication bias5.
In the sensitivity analysis, the confirmed and probable re-clearance groups were merged as re-clearance. 
Logistic regression was fit to assess the robustness of this analysis. All the analyses were conducted in [SAS/STAT] 
Software version [9.4]. All the tests were two-sided at a significance level of 0.05.
Ethics and consent to participate. Data linkage to establish the BC-HTC was performed under the 
BCCDC’s public health mandate. The Behavioral Research Ethics Board at the University of British Columbia 
reviewed and approved the study (H14-01649). All experiments were performed in accordance with the relevant 
guidelines and regulations at BCCDC. Patient consent was not required as study used de-identified linked admin-
istrative healthcare datasets. No identifying information of the study participants has been included in this study.
Data availability. Data are available from the BC Centre for Disease Control Institutional Data Access for 
researchers who meet the criteria for access to confidential data. Requests for the data may be sent to Dr. Naveed 
Janjua (naveed.janjua@bccdc.ca).
Disclaimer. All inferences, opinions, and conclusions drawn in this publication are those of the author(s), and 
do not necessarily reflect the opinions or policies of the [British Columbia] Ministry of Health.
References
 1. Grebely, J. et al. Factors associated with spontaneous clearance of hepatitis C virus among illicit drug users. Canadian J Gastroenterol 
21, 447–451 (2007).
 2. Islam, N. et al. Role of primary T-cell immunodeficiency and hepatitis B coinfection on spontaneous clearance of hepatitis C: The 
BC Hepatitis Testers Cohort. J. Viral Hepat. 24, 421–429 (2017).
 3. Abdel-Hakeem, M. S. & Shoukry, N. H. Protective immunity against hepatitis C: many shades of gray. Front. Immunol. 5, 274 (2014).
 4. Grebely, J. et al. Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards 
a vaccine. Lancet Infect. Dis. 12, 408–414 (2012).
 5. Islam, N. et al. Incidence, risk factors, and prevention of hepatitis C reinfection: a population-based cohort study. Lancet 
Gastroenterol Hepatol 2, 200–210 (2017).
 6. Grady, B. P. et al. Low incidence of reinfection with the hepatitis C virus following treatment in active drug users in Amsterdam. Eur. 
J. Gastroenterol. Hepatol. 24, 1302–1307 (2012).
 7. Grebely, J. et al. Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection. 
Hepatology 55, 1058–1069 (2012).
 8. Marco, A. et al. Hepatitis C virus reinfection among prisoners with sustained virological response after treatment for chronic 
hepatitis C. J. Hepatol. 59, 45–51 (2013).
 9. Sherman, K. E. et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N. Engl. J. Med. 365, 
1014–1024 (2011).
 10. Cunningham, E. B., Applegate, T. L., Lloyd, A. R., Dore, G. J. & Grebely, J. Mixed HCV infection and reinfection in people who inject 
drugs–impact on therapy. Nat Rev Gastroenterol Hepatol 12, 218–230 (2015).
 11. Hill, A., Khoo, S., Fortunak, J., Simmons, B. & Ford, N. Minimum costs for producing hepatitis C direct-acting antivirals for use in 
large-scale treatment access programs in developing countries. Clin. Infect. Dis. 58, 928–936 (2014).
 12. Torresi, J., Johnson, D. & Wedemeyer, H. Progress in the development of preventive and therapeutic vaccines for hepatitis C virus. J. 
Hepatol. 54, 1273–1285 (2011).
 13. Elliott, L. N., Lloyd, A. R., Ziegler, J. B. & Ffrench, R. A. Protective immunity against hepatitis C virus infection. Immunol. Cell Biol. 
84, 239–249 (2006).
 14. Bassett, S. E. et al. Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary 
infection. Hepatology 33, 1479–1487 (2001).
 15. Lanford, R. E. et al. Cross-genotype immunity to hepatitis C virus. J. Virol. 78, 1575–1581 (2004).
 16. Prince, A. M. et al. Protection against chronic hepatitis C virus infection after rechallenge with homologous, but not heterologous, 
genotypes in a chimpanzee model. J. Infect. Dis. 192, 1701–1709 (2005).
 17. Osburn, W. O. et al. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. 
Gastroenterology 138, 315–324 (2010).
 18. Page, K. et al. Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, 
resolution, and reinfection. J. Infect. Dis. 200, 1216–1226 (2009).
www.nature.com/scientificreports/
7Scientific RepoRts | 7: 12326  | DOI:10.1038/s41598-017-10190-8
 19. Abdel-Hakeem, M. S., Bedard, N., Murphy, D., Bruneau, J. & Shoukry, N. H. Signatures of protective memory immune responses 
during hepatitis C virus reinfection. Gastroenterology 147, 870–881 (2014).
 20. Midgard, H. et al. Hepatitis C reinfection after sustained virological response. J. Hepatol. 64, 1020–1026 (2016).
 21. Grebely, J. et al. Hepatitis C virus reinfection in injection drug users. Hepatology 44, 1139–1145 (2006).
 22. Sacks-Davis, R. et al. Hepatitis C Virus Reinfection and Spontaneous Clearance of Reinfection–the InC3 Study. J. Infect. Dis. 212, 
1407–1419 (2015).
 23. Sacks-Davis, R. et al. High rates of hepatitis C virus reinfection and spontaneous clearance of reinfection in people who inject drugs: 
a prospective cohort study. PLoS One 8, e80216 (2013).
 24. Piasecki, B. A. et al. Influence of alcohol use, race, and viral coinfections on spontaneous HCV clearance in a US veteran population. 
Hepatology 40, 892–899 (2004).
 25. Szabo, G. & Mandrekar, P. A recent perspective on alcohol, immunity, and host defense. Alcohol. Clin. Exp. Res. 33, 220–232 (2009).
 26. Szabo, G. et al. Hepatitis C infection and alcohol use: A dangerous mix for the liver and antiviral immunity. Alcohol. Clin. Exp. Res. 
30, 709–719 (2006).
 27. Werner, J. M., Abdalla, A., Gara, N., Ghany, M. G. & Rehermann, B. The hepatitis B vaccine protects re-exposed health care workers, 
but does not provide sterilizing immunity. Gastroenterology 145, 1026–1034 (2013).
 28. Janjua, N. Z. et al. Assessing hepatitis C burden and treatment effectiveness through the British Columbia Hepatitis Testers Cohort 
(BC-HTC): design and characteristics of linked and unlinked participants. PLoS One 11, e0150176 (2016).
 29. Janjua N. Z. et al. Amanda Yu, Margot Kuo, Maria Alvarez, Darrel Cook, Jason Wong, Mark W. Tyndall, Mel Krajden. Twin 
epidemics of new and prevalent hepatitis C infections in Canada: BC Hepatitis Testers Cohort. BMC Infectious Diseases 16(1) 
(2016).
 30. Zeuzem, S. et al. Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with 
interferon α for chronic hepatitis C. J. Hepatol. 39, 106–111 (2003).
 31. BC Centre for Disease Control. STI/HIV Prevention and Control. In Communicable Disease Control Manual (BC Centre for Disease 
Control, Vancouver, Canada, 2013).
Acknowledgements
We thank Dr. Naglaa H. Shoukry for her review with insightful feedback that significantly improved the 
manuscript. This work was supported by British Columbia Centre for Disease Control and Agencies 
contributing data to the study and the Canadian Institutes of Health Research [Grant #201503NHC-348216-
NHC-ADWY-62134 & 201410PHE-337680-PHE-CAAA-179547]. NI is supported by Vanier Canada Doctoral 
Scholarship from Canadian Institutes of Health Research (CIHR).
Author Contributions
N.I., N.Z.J., M.K., J.S., P.G., and M.G. conceptualised and designed the study. N.I., N.Z.J., M.Kr., J.S., P.G., M.G., 
J.W., M.W.T., The BC-HTC Team were involved in acquisition, analysis, or interpretation of data. N.I. did the 
statistical analysis and wrote the first draft of the manuscript. All authors critically revised the manuscript for 
significant intellectual contents.
Additional Information
Supplementary information accompanies this paper at doi:10.1038/s41598-017-10190-8
Competing Interests: M.K. has received grant funding via his institution from Roche Molecular Systems, 
Boehringer Ingelheim, Merck, Siemens Healthcare Diagnostics and Hologic Inc. P.G. has received consulting 
fees from ICON Plc and Biogen. However, these funding agencies had no control over any aspects of this 
manuscript.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2017
www.nature.com/scientificreports/
8Scientific RepoRts | 7: 12326  | DOI:10.1038/s41598-017-10190-8
Consortia
The BC-HTC Team
Amanda Yu2, Margot Kuo2, Maria Alvarez2, Mei Chong2, Zahid A. Butt2, Nabin Shrestha2, 
Hasina Samji2 & Seyed Ali Mussavi Rizi8
8Performance Measurement & Reporting, Provincial Health Services Authority, Vancouver, BC, Canada. 
